Related Experiment Video
Updated: May 14, 2026

Applying an Inducible Expression System to Study Interference of Bacterial Virulence Factors with Intracellular Signaling
Published on: June 25, 2015
Vector-mediated selective expression of lethal factor, a toxic element of Bacillus anthracis, damages A549 cells via
Wenlei Zhuo1, Guangli Tao, Liang Zhang
1Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, China. zhuowenlei@yahoo.com.cn
Abstract:
Lethal factor (LF), a major toxic element of Bacillus anthracis combined with its protective antigen (PA), enters the cells through the cytomembrane receptors and causes damage to the host cells, thereby leading to septicemia, toxemia, and meningitis with high mortality. LF has been identified as a potential biotech-weapon, which can impede cancer growth in vascular endothelial cells because of its cytotoxicity. However, the feasibility of LF application and further investigations has been limited because LF is nonspecific. To solve this problem, we constructed a vector that contained the LF sequence, which was regulated by a tumor-specific human telomerase reverse transcriptase promoter (hTERTp). Results showed that LF was selectively expressed in lung cancer A549 cells but not in normal cells, thereby resulting in A549 cell apoptosis. The results also revealed that the inhibition of mitogen-activated protein kinase and AKT pathways was partially involved in the process. Thus, hTERTp-regulated LF increase could be a promising approach in lung cancer-targeted therapy.
Insights
Bacillus anthracis lethal factor (LF) was engineered for targeted lung cancer therapy. A tumor-specific promoter ensured LF expression only in cancer cells, inducing apoptosis and offering a promising new treatment strategy.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Bacillus anthracis lethal factor (LF) is cytotoxic and has potential anti-cancer applications.
- LF's non-specific action limits its therapeutic use.
- Targeted delivery systems are needed to harness LF's cytotoxicity for cancer treatment.
Purpose of the Study:
- To develop a targeted delivery system for LF to treat lung cancer.
- To investigate the selective expression and efficacy of LF in lung cancer cells using a tumor-specific promoter.
Main Methods:
- Constructed a vector containing the LF sequence regulated by the human telomerase reverse transcriptase promoter (hTERTp).
- Expressed the engineered LF in lung cancer A549 cells and normal cells.
- Analyzed cell apoptosis and the involvement of mitogen-activated protein kinase (MAPK) and AKT pathways.
Main Results:
- LF was selectively expressed in A549 lung cancer cells, not in normal cells.
- Selective LF expression induced apoptosis in A549 cells.
- Inhibition of MAPK and AKT pathways was partially implicated in the observed cell death.
Conclusions:
- hTERTp-regulated LF expression is a feasible strategy for targeted lung cancer therapy.
- This approach offers a promising avenue for developing novel anti-cancer treatments by leveraging LF's cytotoxicity.
- Further research into the underlying molecular mechanisms could optimize this therapeutic strategy.
Related Concept Videos
Bacterial Toxins
MAPK Signaling Cascades
The Intrinsic Apoptotic Pathway
Regulation of Bacterial Virulence
The Extrinsic Apoptotic Pathway
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...

